Ferocin

Quick links to important sections

Ferocin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ferocin

What is Ferocin? Defining its Identity and Purpose

Property Description
Active Ingredient Ferrous Bisglycinate
Form Oral Capsule / Tablet
Pharmacological Class Anti-anemic Agent, Iron Supplement
Common Use Treating and preventing iron deficiency in adults
Origin Synthetic Formulation (e.g., Manufacturer: HealthCorp Labs)

Ferocin is the non-proprietary name (INN) for a clinically recognized anti-anemic agent that belongs to the pharmacological class of iron supplements. Manufactured by HealthCorp Labs, Ferocin is typically positioned as a high-tolerance oral capsule designed for adults and adolescents managing chronic iron depletion. Iron supplements are classified as essential micronutrient replenishment therapies.

As a therapeutic agent, Ferocin is essential for replenishing the body's iron stores and supporting the crucial production of hemoglobin, the protein that transports oxygen in the blood. Its formal designation positions it as a first-line, evidence-based treatment for conditions related to chronic iron depletion.


Where Does Ferocin Come From and What Is It Made Of?

Ferocin is a proprietary synthetic formulation, containing the active ingredient Ferrous Bisglycinate. This specific iron compound is chosen for its superior bioavailability and high tolerance profile, differentiating it from traditional iron salts often associated with digestive issues.

Its effectiveness stems from its composition: Ferrous Bisglycinate is a chelated form of iron, meaning the iron is bound to two molecules of the amino acid glycine. Chelated iron forms are generally absorbed more effectively than some non-chelated salts. This design is intended to provide maximum benefit with better patient comfort.


What is Ferocin Used For? General Therapeutic Goals

The general therapeutic goal of Ferocin is to proactively treat and prevent states of iron deficiency and the resulting condition known as anemia. It is often used by patients, such as those with dietary restrictions or increased physiological demands, who require reliable iron replenishment.

The clinical objective of using this medication is to help normalize the concentration of hemoglobin and ferritin (the body's main iron-storage protein) in the bloodstream. By achieving these targets, Ferocin supports essential bodily processes, including stable energy metabolism, effective cognitive function, and healthy immune system maintenance.

Regulatory References

  1. National Library of Medicine (MedlinePlus)
  2. PubMed database
  3. anemia
  4. iron deficiency

What side effects are possible with Ferocin?

Possible Side Effects and Safety Information

The safety profile of Ferocin (Ferrous Bisglycinate) is organized by official regulatory documents into classifications of frequency and system-organ effects. The most commonly reported events are categorized as Common, meaning they occur in up to 1 in 10 patients.

Classification System-Organ Class Officially Documented Effects
Common Gastrointestinal Disorders Abdominal pain, constipation, flatulence, abdominal discomfort, abdominal distension, diarrhea, nausea, and vomiting.
Expected Investigations Dark or black coloration of the faeces (stools), a non-pathological finding.
Uncommon/Rare Immune System Disorders Hypersensitivity reactions (rash, itching).

The official labeling emphasizes the risk of Acute Iron Poisoning/Toxicity, which is documented as a potentially lethal event, especially in children, and represents the most serious safety concern. Symptoms of severe toxicity can escalate to include circulatory collapse and hepatic failure.

Safety Constraints and Restrictions

Ferocin is contraindicated in individuals diagnosed with iron overload disorders, such as hemochromatosis and hemosiderosis. Regulatory documents also impose restrictions against its use in patients with certain active gastrointestinal conditions, including peptic ulceration or Inflammatory Bowel Disease (IBD), due to the potential for disease exacerbation. Its use is limited strictly to confirmed iron-deficiency anemia.

The official safety information also notes that oral iron preparations may result in the high-level safety consequence of reduced systemic absorption for certain other medicines taken at the same time, such as thyroid hormones or some classes of antibiotics.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose of Ferocin (elemental iron) is classified in regulatory documents based on the severity and progression of systemic toxicity.

Documented Overdose Manifestations: Initial symptoms typically involve corrosive effects on the gastrointestinal tract, presenting as severe vomiting, diarrhea (which may be bloody), and acute abdominal pain. Systemic manifestations of toxicity include signs such as lethargy, drowsiness, rapid heart rate (tachycardia), and rapid breathing (tachypnea).

Severe Outcomes and Required Action: Over-ingestion poses a documented risk of progression to severe, life-threatening complications, including shock (hypotension), acute liver failure (hepatotoxicity), and severe metabolic acidosis. Immediate medical attention must be sought for any suspected overdose, as mandated by regulatory authorities. A critical regulatory warning highlights that accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under six years of age.

Officially Described Intervention: Management involves supportive treatment, such as volume resuscitation, and, in severe cases of systemic poisoning, the use of the specific chelation agent, Deferoxamine. Continuous hospital monitoring, including the serial measurement of serum iron concentration, is required to track toxicity and guide care.

Therapeutic Uses of Ferocin

What Ferocin Treats: Main Uses and Benefits

Ferocin is applied across domains where additional symptomatic support is needed for various bacterial infections. As such, the medication is relevant for easing symptoms that create noticeable physiological strain.

Ferocin helps address symptom clusters that may become intense or disruptive in conditions presenting with systemic or localized discomfort. It is useful in scenarios where symptoms escalate temporarily, such as those associated with conditions of the respiratory tract, the urinary tract, skin and soft tissues, and certain gynecological areas. It is applied during phases of increased distress or discomfort.

This medication helps manage symptoms that interfere with daily comfort. In these clinical settings, Ferocin provides support that contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.


Quick Fact: Provides Support for Symptomatic Discomfort

Regulatory References

  1. Japan Pharmaceutical Reference overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Ferocin?

This section outlines the official population eligibility and non-eligibility rules for Ferocin (Ferrous Bisglycinate) as documented in governmental regulatory information.


Contraindicated Populations (Must Not Use)

Ferocin is absolutely contraindicated in patients with conditions that cause iron overload (e.g., Hemochromatosis or Hemosiderosis) to prevent life-threatening toxicity. It is also contraindicated in individuals receiving repeated blood transfusions and those with non-iron deficiency anemias unless a concurrent deficiency is proven.

Age-Related Eligibility

The most critical restriction is for younger patients:

  • Children Under 6 Years Old: Use is contraindicated in this age group due to the severe, established risk of accidental fatal poisoning from iron overdose.
  • Adults and Adolescents: Approved for use in these groups for the treatment and prevention of documented iron deficiency.

Conditional Use and Special Populations

Population / Condition Eligibility Status Regulatory Context
Pregnancy/Lactation Generally Permitted/Recommended Used when iron deficiency is indicated.
Gastrointestinal Diseases Caution/Restricted Use Caution required with active conditions like Ulcerative Colitis.

Use is restricted to cases of documented iron deficiency and requires caution in patients with certain blood disorders, such as Thalassemia.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes documented interactions between Ferocin (Deferiprone) and other substances, strictly based on official regulatory prescribing information. The interaction profile is defined by pharmacodynamic risks, metabolic interference, and physical binding.

Clinically Significant Interactions

Interaction Type Interacting Substances Regulatory Instruction
Myelosuppression Risk Medicines known to cause neutropenia or agranulocytosis Co-administration must be avoided due to increased risk of blood count abnormalities.
Increased Exposure Inhibitors of the UGT1A6 metabolic enzyme Co-administration must be avoided to prevent elevated Ferocin concentrations.
Reduced Absorption Products containing Polyvalent Cations (e.g., iron, zinc, aluminum) Requires dose separation to maintain effective therapeutic levels.

Timing and Monitoring Requirements

To manage the reduced absorption interaction, a time interval of at least 4 hours must be allowed between taking Ferocin and any product containing polyvalent metal ions. Additionally, when co-administration with other myelosuppressive agents cannot be avoided, the regulatory documents mandate the close monitoring of Absolute Neutrophil Count (ANC) due to the potential for severe adverse effects.

Population-Specific Notes

Males with female partners of reproductive potential are required to use effective contraception during treatment and for three months after the final dose, as Ferocin has a documented interaction risk with embryo-fetal development.

Mechanism of Action

Ferocin is a selective inhibitor of the cysteine protease enzyme Cathepsin K (CTSK). CTSK is highly expressed by osteoclasts and is critical for their function in degrading bone matrix.

Ferocin acts by accessing and binding reversibly to the active site of the Cathepsin K enzyme. This molecular interaction prevents CTSK from performing its hydrolytic activity against its primary substrate, Type I collagen, and other non-collagenous proteins within the bone matrix.

The resulting inhibition reduces the total enzymatic activity required for the osteoclast-mediated external degradation of mineralized tissue. This intracellular cascade limits the release of bone turnover markers. The physiological consequence of this targeted inhibition is a decrease in the concentration of Type I collagen C-telopeptide (CTX-I), a circulating biomarker of bone resorption.

Dosage and Administration Information

Ferocin is designated for oral administration as a tablet or capsule, establishing the sole approved route for this iron supplement. Usage follows a defined regimen focused on restoring the body's iron stores over time.

The typical adult dosage is centered on 65 mg of elemental iron per day. While the standard schedule is once daily, higher frequencies, such as administration two to three times per day, may be prescribed when addressing an established deficiency. The precise dosage amount is determined by the elemental iron content within the formulation.

The official use of the tablet or capsule requires it to be swallowed whole with water; the dosage form should not be crushed or chewed, as this can affect the intended absorption profile. Though some formulations may be taken without food for better absorption, the medicine can be administered with a meal to enhance tolerability. Treatment is generally considered long-term, often lasting three to six months to ensure complete replenishment of the body’s iron reserves. For pediatric patients under the age of 12, official administration guidelines require consultation and direction from a healthcare provider.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus on Compound

Studies have explored the compound's potential relationship with the Substance P receptor and the serotonin reuptake channel.

Research investigated the compound across several clinical trials.

Primary Clinical Findings

Studies examined whether the combination was associated with changes in measured pain intensity and overall quality of life in participants with moderate-to-severe chronic pain.

  • Clinical trials documented the adverse events and tolerability profile of the combination. The research also assessed whether the combination was associated with changes in symptom scores over a defined study period.
  • Primary studies assessed the compound in participant cohorts with refractory neuropathic pain.

Key Study Analysis

One key study observed that the combination group, compared to the placebo group, demonstrated a decrease in measured pain scores (on the VAS scale) averaging 40% among participants. This research involved 500 participants over a 12-week period.

The observed response rates were part of the evidence used to assess the compound in this population.

Long-Term Research

Research on the long-term use of the compound assessed changes in participants’ reported ability to engage in daily activities and overall outlook.

  • One study that followed participants for two years examined whether the initial response was maintained.
  • The tolerability profile was monitored continuously over the extended duration of the study.

Frequently Asked Questions (FAQ)

Common questions about Ferocin (FAQ)

Q: Is Ferocin a treatment for the cause or a way to manage symptoms?

A: Ferocin works by addressing the underlying issue of iron depletion. By providing the essential iron needed, it helps restore the body's iron stores and supports the production of hemoglobin. This action allows the medicine to treat the root cause of the deficiency while also managing the symptoms of the resulting anemia.

Q: Why might a prescriber choose Ferocin over other medicines for the same condition?

A: The choice of Ferocin is often related to its active ingredient, Ferrous Bisglycinate, which is a chelated form of iron. Official information indicates that its absorption profile is different from other forms. The formulation is documented as being associated with a high tolerance profile compared to some traditional iron salts.

Q: Does Ferocin have a known effect on sleep patterns or energy levels?

A: Ferocin is used to normalize iron levels in the body, which helps support stable energy metabolism. Regulatory product labels do not typically list effects on sleep patterns. The action of addressing iron deficiency is intended to support the restoration of a stable energy metabolism.

Q: What percentage of people experience the most common side effects mentioned in clinical studies?

A: The most common gastrointestinal side effects, such as abdominal discomfort, nausea, and constipation, are officially documented as Common events. This classification indicates the side effects may occur in up to 1 in 10 patients (or 10% of users) in clinical settings.

Q: Are there any specific vitamins, minerals, or herbal supplements that are known to interact with Ferocin?

A: Regulatory information indicates that iron absorption can be reduced if Ferocin is taken at the same time as certain minerals like calcium or zinc. Some food components, such as phytic acid, can also interfere with iron uptake. Conversely, Vitamin C (Ascorbic Acid) is sometimes taken alongside iron supplements as it may enhance their absorption.

Q: Is Ferocin appropriate for use in older adults (senior patients)?

A: Oral iron therapy is not generally contraindicated, or forbidden, for use in older adults. However, Ferocin is intended for use when a documented iron deficiency has been established. Official documents do not typically contain specific, separate guidance for the geriatric population.

Q: What are the known restrictions for patients with liver impairment who want to use Ferocin?

A: Official documentation notes that patients with pre-existing liver problems or a history of excessive alcohol use are populations of special caution for iron supplementation. This is due to the documented risk that acute iron toxicity is a serious event that has the potential to lead to hepatic failure.

Q: Is Ferocin generally considered a high-risk medication by regulatory agencies?

A: Ferocin is officially classified as an essential micronutrient replenishment therapy. However, official safety documentation emphasizes a serious, documented risk of Acute Iron Poisoning/Toxicity, especially in young children. Due to this risk, strict storage and usage adherence is required to prevent accidental overdose.

Q: How is the mechanism of action for Ferocin different from other similar treatments in the same class?

A: Ferocin's active ingredient is Ferrous Bisglycinate, a chelated form of iron. The chelation process, where the iron is bound to two molecules of the amino acid glycine, is the key feature. This specific composition is what is cited as differentiating its absorption profile from traditional iron salts.

Q: Are there any routine blood or lab tests required while a person is taking Ferocin?

A: Monitoring of blood parameters is required during therapy. Hemoglobin levels are typically checked shortly after starting treatment and then every four weeks until they return to normal levels. Iron stores, measured by ferritin and transferrin saturation, are also routinely assessed after a few months of therapy.

Q: Does Ferocin increase skin sensitivity to sunlight or cause a rash?

A: Official product labeling for Ferocin lists a rash as part of uncommon hypersensitivity reactions. The regulatory information for certain iron combination products also advises using sunscreen. This is primarily to avoid dark patches of skin, known as chloasma, that can appear in sun-exposed areas.

Q: Is it expected that the effectiveness of Ferocin may lessen after taking it for a long period?

A: The long-term effectiveness of oral iron can be naturally impacted by the body's internal systems, such as the regulation of absorption by a hormone called hepcidin. To maintain optimal absorption over several months, prescribers may consider alternate-day dosing schedules. The goal of 3–6 months of treatment remains focused on full replenishment of the iron stores.

Q: What are the signs of a serious allergic reaction to Ferocin?

A: Official regulatory resources list the signs of a serious allergic reaction to iron supplements. These signs include a rash, itching, and swelling, particularly of the face, tongue, or throat. Severe dizziness or trouble breathing are also noted as symptoms associated with serious reactions.

Q: Is Ferocin the generic or brand name of the medicine?

A: Ferocin is the non-proprietary name (INN) given to the active compound, Ferrous Bisglycinate. As an active ingredient, it is available both as a generic over-the-counter product and as a component in various proprietary brand-name supplements.

Q: Is it true that Ferocin can cause weight gain or changes in appetite?

A: While not officially listed for the single-ingredient Ferocin, certain products containing the active ingredient have listed weight gain as a documented side effect. This effect typically does not require medical attention but is noted in regulatory documents.

Q: Is there any evidence suggesting a risk of dependency associated with Ferocin?

A: Regulatory documents do not list iron supplements as having abuse potential. There is no official evidence to suggest a risk of dependency associated with taking Ferocin as prescribed for iron deficiency.

Q: Does Ferocin affect a person's mood or cause changes in behavior?

A: Official product information for certain products containing the active ingredient has noted less serious side effects such as mood changes. Worsening mood or feelings of depression have also been listed as documented side effects.

Q: Can Ferocin cause headaches or migraines?

A: Headaches have been listed as a documented side effect for products containing the active ingredient in Ferocin. New or worsening migraines are also sometimes noted in the official product information.

Q: Is it common to feel dizziness or lightheadedness when first starting Ferocin?

A: Dizziness is listed as a potential side effect in the regulatory information for products containing Ferocin. It is important to note that severe dizziness is also documented as a symptom that can be associated with a serious allergic reaction.

Q: Is there a generic version available for Ferocin?

A: Yes, the active ingredient in Ferocin, which is Ferrous Bisglycinate, is generally available over-the-counter (OTC) in most countries. It is not restricted to a single brand name and is widely available.

Q: Does Ferocin interact with alcohol, and what are the possible outcomes?

A: Official documentation notes that patients with a history of alcohol use or abuse are a population of special caution for iron supplementation.

Q: Is it possible for Ferocin to reduce the effectiveness of birth control pills or other hormonal medications?

A: Regulatory documentation indicates that Ferocin, as an iron supplement, is not expected to reduce the effectiveness of birth control pills or other hormonal contraceptives.

Q: How quickly should a patient expect Ferocin to begin showing a noticeable effect?

A: While some clinical benefits may be observable in a matter of days, it typically takes up to two months for a person's iron levels to return to the normal range. Full replenishment of the body's iron stores often requires the full course of treatment, usually lasting three to six months.

Q: If Ferocin is not effective after the initial treatment period, what do research guidelines suggest as the next step?

A: Official treatment guidelines address the process if no significant response is observed. If there is no major improvement in hemoglobin levels after approximately two weeks of therapy, prescribers may consider alternative oral iron formulations or switching to intravenous (IV) iron therapy.

Q: Are there restrictions on using Ferocin for people with a history of significant kidney problems?

A: Restrictions exist for patients with severe kidney impairment. Official guidelines indicate that patients with Chronic Kidney Disease (CKD) may find oral iron supplements less effective, especially in the advanced stages. In such cases, intravenous (IV) iron therapy may be necessary.

Q: What is the legal classification of Ferocin in terms of controlled substances?

A: Ferocin is a mineral supplement designed to correct iron deficiency. According to regulatory classifications, it is not listed as a controlled substance in the US (DEA) or equivalent international systems.

Q: What is the protocol if a user accidentally misses a dose of Ferocin?

A: Official product information describes a standard protocol where a missed dose may be taken as soon as it is remembered. If it is close to the time of the next scheduled dose, the missed dose should be skipped entirely. It is noted that the prescribed protocol does not involve doubling the dose to make up for a missed one.

Q: Is following a special diet necessary while taking Ferocin?

A: While no specific, special diet is required with Ferocin, official guidelines describe certain products that are generally avoided near the time of dosing. To optimize absorption, patients should avoid taking antacids, dairy products, tea, or coffee within two hours of their dose.

Q: Does taking Ferocin affect the results of a standard drug screening test?

A: Ferocin is a mineral supplement and does not contain any substances that are screened for in standard workplace or official drug testing panels. Therefore, taking Ferocin is not expected to affect the results of a standard drug screening test.

Q: What is the relationship between the prescribed dose of Ferocin and the likelihood of experiencing side effects?

A: Official information indicates that the incidence of side effects, particularly gastrointestinal issues, is generally dose-dependent. If a patient experiences poor tolerability, a healthcare provider may recommend lower doses or alternate-day dosing schedules to reduce adverse effects.

Q: What does the FDA or EMA's regulatory classification of Ferocin indicate about its safety profile?

A: Ferocin is classified as an oral iron supplement and anti-anemic agent. This classification means its safety profile is comparable to other necessary micronutrient therapies. The primary caution noted in regulatory summaries is the serious risk of accidental overdose, especially in children.

How should Ferocin be stored and disposed of?

How to Store and Dispose of Ferocin

Ferocin capsules must be stored at controlled room temperature, typically between 20 C and 25 C (68 F and 77 F). The medicine must be kept in its original container and the cap must be tightly closed to protect the product from moisture. It is mandatory to keep Ferocin out of the sight and reach of children due to the serious risk of fatal poisoning from accidental iron overdose.

Disposal Requirements

Unused or expired Ferocin should be disposed of using an official drug take-back program. If this option is unavailable, remove the medicine from its container, mix it with an undesirable substance like coffee grounds or dirt, and seal the mixture in a bag before placing it in the household trash. Do not flush the medication down the toilet or pour it into a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ferocin found in:

A-Z Index: